Refine
Year of publication
Document Type
- Article (35)
- Preprint (14)
- diplomthesis (1)
- Doctoral Thesis (1)
Has Fulltext
- yes (51) (remove)
Is part of the Bibliography
- no (51) (remove)
Keywords
- LHC (3)
- ALICE (2)
- Podospora anserina (2)
- aging (2)
- mitochondria (2)
- 900 GeV (1)
- ACLF (1)
- ADHD (1)
- Atoms (1)
- Buprestidae (1)
- CNVs (1)
- Cerambycidae (1)
- Drug development (1)
- Electroantennography (1)
- Electron-pion identification (1)
- Endothelprogenitorzellen (1)
- Femtoscopy (1)
- Fibre/foam sandwich radiator (1)
- GWAS (1)
- Gentherapie (1)
- Gerinnungsfaktor VIII (1)
- Grün fluoreszierendes Protein (1)
- HBT (1)
- Heavy Ions (1)
- Heavy-ion collisions (1)
- Immortalisierung (1)
- Intensity interferometry (1)
- Intrazellulärer Transport (1)
- Ionisation energy loss (1)
- Ions (1)
- Long-term follow up (1)
- MICOS (1)
- Monochamus galloprovincialis (1)
- Multi-wire proportional drift chamber (1)
- Neural network (1)
- Nuclear modification factor (1)
- PARK2 (1)
- PYTHIA (1)
- Paediatric Investigation Plan (1)
- Paediatric oncology (1)
- Pb–Pb (1)
- Perturbative methods (1)
- Phaenops cyanea (1)
- Precompetitive development (1)
- Promotor <Genetik> (1)
- QCD (1)
- Quark gluon plasma (1)
- Regulatory framework (1)
- Scattering of atoms, molecules, clusters & ions (1)
- Scattering theory (1)
- TR (1)
- Telomerase (1)
- Tracking (1)
- Transition radiation detector (1)
- Transverse momentum (1)
- Trigger (1)
- Xenon-based gas mixture (1)
- acute decompensation (1)
- advanced care planning (1)
- atherosclerosis (1)
- bortezomib (1)
- central nervous system infection (1)
- children (1)
- cirrhosis (1)
- coagulation factor VIII (1)
- coronary disease (1)
- cristae (1)
- dE/dx (1)
- day clinic (1)
- diagnosis (1)
- disease progression (1)
- gene therapy (1)
- guideline (1)
- i-AAA protease (1)
- immortalization (1)
- immunocompromised patient (1)
- induction regimen (1)
- intracellular transport (1)
- kidney (1)
- lenalidomide (1)
- lentiviraler Vektor (1)
- mitohormesis (1)
- multimodal complex treatment (1)
- multiple myeloma (1)
- networks (1)
- organ dysfunction (1)
- organ failure (1)
- promoter (1)
- protein quality control (1)
- renal failure (1)
- risk assessment (1)
- signature (1)
- temperature (1)
- tomography (1)
- treatment (1)
- vascular calcification (1)
- √sN N = 2.76 TeV (1)
Institute
- Physik (28)
- Frankfurt Institute for Advanced Studies (FIAS) (24)
- Informatik (24)
- Medizin (14)
- Geowissenschaften (4)
- Biowissenschaften (2)
- ELEMENTS (2)
- Mathematik (1)
- Pharmazie (1)
The link between atmospheric radicals and newly formed particles at a spruce forest site in Germany
(2014)
It has been claimed for more than a century that atmospheric new particle formation is primarily influenced by the presence of sulfuric acid. However, the activation process of sulfuric acid related clusters into detectable particles is still an unresolved topic. In this study we focus on the PARADE campaign measurements conducted during August/September 2011 at Mt Kleiner Feldberg in central Germany. During this campaign a set of radicals, organic and inorganic compounds and oxidants and aerosol properties were measured or calculated. We compared a range of organic and inorganic nucleation theories, evaluating their ability to simulate measured particle formation rates at 3 nm in diameter (J3) for a variety of different conditions. Nucleation mechanisms involving only sulfuric acid tentatively captured the observed noon-time daily maximum in J3, but displayed an increasing difference to J3 measurements during the rest of the diurnal cycle. Including large organic radicals, i.e. organic peroxy radicals (RO2) deriving from monoterpenes and their oxidation products, in the nucleation mechanism improved the correlation between observed and simulated J3. This supports a recently proposed empirical relationship for new particle formation that has been used in global models. However, the best match between theory and measurements for the site of interest was found for an activation process based on large organic peroxy radicals and stabilised Criegee intermediates (sCI). This novel laboratory-derived algorithm simulated the daily pattern and intensity of J3 observed in the ambient data. In this algorithm organic derived radicals are involved in activation and growth and link the formation rate of smallest aerosol particles with OH during daytime and NO3 during night-time. Because the RO2 lifetime is controlled by HO2 and NO we conclude that peroxy radicals and NO seem to play an important role for ambient radical chemistry not only with respect to oxidation capacity but also for the activation process of new particle formation. This is supposed to have significant impact of atmospheric radical species on aerosol chemistry and should be taken into account when studying the impact of new particles in climate feedback cycles.
Seven years after the launch of the European Paediatric Medicine Regulation, limited progress in paediatric oncology drug development remains a major concern amongst stakeholders – academics, industry, regulatory authorities, parents, patients and caregivers. Restricted increases in early phase paediatric oncology trials, legal requirements and regulatory pressure to propose early Paediatric Investigation Plans (PIPs), missed opportunities to explore new drugs potentially relevant for paediatric malignancies, lack of innovative trial designs and no new incentives to develop drugs against specific paediatric targets are some unmet needs. Better access to new anti-cancer drugs for paediatric clinical studies and improved collaboration between stakeholders are essential. The Cancer Drug Development Forum (CDDF), previously Biotherapy Development Association (BDA), with Innovative Therapy for Children with Cancer Consortium (ITCC), European Society for Paediatric Oncology (SIOPE) and European Network for Cancer Research in Children and Adolescents (ENCCA) has created a unique Paediatric Oncology Platform, involving multiple stakeholders and the European Union (EU) Commission, with an urgent remit to improve paediatric oncology drug development. The Paediatric Oncology Platform proposes to recommend immediate changes in the implementation of the Regulation and set the framework for its 2017 revision; initiatives to incentivise drug development against specific paediatric oncology targets, and repositioning of drugs not developed in adults. Underpinning these changes is a strategy for mechanism of action and biology driven selection and prioritisation of potential paediatric indications rather than the current process based on adult cancer indications. Pre-competitive research and drug prioritisation, early portfolio evaluation, cross-industry cooperation and multi-compound/sponsor trials are being explored, from which guidance for innovative trial designs will be provided.
Unmasking a temperature-dependent effect of the P. anserina i-AAA protease on aging and development
(2011)
Different molecular pathways involved in maintaining mitochondrial function are of fundamental importance to control cellular homeostasis. Mitochondrial i-AAA protease is part of such a surveillance system, and PaIAP is the putative ortholog in the fungal aging model Podospora anserina. Here, we investigate the role of PaIAP in aging and development. Deletion of the gene encoding PaIAP resulted in a specific phenotype. When incubated at 27°C, spore germination and fruiting body formation are not different from that of the corresponding wild-type strain. Unexpectedly, the lifespan of the deletion strain is strongly increased. In contrast, cultivation at an elevated temperature of 37°C leads to impairments in spore germination and fruiting body formation and to a reduced lifespan. The higher PaIAP abundance in wild-type strains of the fungus grown at elevated temperature and the phenotype of the deletion strain unmasks a temperature-related role of the protein. The protease appears to be part of a molecular system that has evolved to allow survival under changing temperatures, as they characteristically occur in nature.
Introduction: Evidence from a number of open-label, uncontrolled studies has suggested that rituximab may benefit patients with autoimmune diseases who are refractory to standard-of-care. The objective of this study was to evaluate the safety and clinical outcomes of rituximab in several standard-of-care-refractory autoimmune diseases (within rheumatology, nephrology, dermatology and neurology) other than rheumatoid arthritis or non-Hodgkin's lymphoma in a real-life clinical setting.
Methods: Patients who received rituximab having shown an inadequate response to standard-of-care had their safety and clinical outcomes data retrospectively analysed as part of the German Registry of Autoimmune Diseases. The main outcome measures were safety and clinical response, as judged at the discretion of the investigators.
Results: A total of 370 patients (299 patient-years) with various autoimmune diseases (23.0% with systemic lupus erythematosus, 15.7% antineutrophil cytoplasmic antibody-associated granulomatous vasculitides, 15.1% multiple sclerosis and 10.0% pemphigus) from 42 centres received a mean dose of 2,440 mg of rituximab over a median (range) of 194 (180 to 1,407) days. The overall rate of serious infections was 5.3 per 100 patient-years during rituximab therapy. Opportunistic infections were infrequent across the whole study population, and mostly occurred in patients with systemic lupus erythematosus. There were 11 deaths (3.0% of patients) after rituximab treatment (mean 11.6 months after first infusion, range 0.8 to 31.3 months), with most of the deaths caused by infections. Overall (n = 293), 13.3% of patients showed no response, 45.1% showed a partial response and 41.6% showed a complete response. Responses were also reflected by reduced use of glucocorticoids and various immunosuppressives during rituximab therapy and follow-up compared with before rituximab. Rituximab generally had a positive effect on patient well-being (physician's visual analogue scale; mean improvement from baseline of 12.1 mm).
Conclusions: Data from this registry indicate that rituximab is a commonly employed, well-tolerated therapy with potential beneficial effects in standard of care-refractory autoimmune diseases, and support the results from other open-label, uncontrolled studies.
Measurements of OH, total peroxy radicals, non-methane hydrocarbons (NMHCs) and various other trace gases were made at the Meteorological Observatory Hohenpeissenberg in June 2000. The data from an intensive measurement period characterised by high solar insolation (18-21 June) are analysed. The maximum midday OH concentration ranged between 4.5x106 molecules cm-3 and 7.4x106 molecules cm-3. The maximum total ROx (ROx =OH+RO+HO2+RO2) mixing ratio increased from about 55 pptv on 18 June to nearly 70 pptv on 20 and 21 June. A total of 64 NMHCs, including isoprene and monoterpenes, were measured every 1 to 6 hours. The oxidation rate of the NMHCs by OH was calculated and reached a total of over 14x106 molecules cm-3 s-1 on two days. A simple photostationary state balance model was used to simulate the ambient OH and peroxy radical concentrations with the measured data as input. This approach was able to reproduce the main features of the diurnal profiles of both OH and peroxy radicals. The balance equations were used to test the effect of the assumptions made in this model. The results proved to be most sensitive to assumptions about the impact of unmeasured volatile organic compounds (VOC), e.g. formaldehyde (HCHO), and about the partitioning between HO2 and RO2. The measured OH concentration and peroxy radical mixing ratios were reproduced well by assuming the presence of 3 ppbv HCHO as a proxy for oxygenated hydrocarbons, and a HO2/ RO2 ratio between 1:1 and 1:2. The most important source of OH, and conversely the greatest sink for peroxy radicals, was the recycling of HO2 radicals to OH. This reaction was responsible for the recycling of more than 45x106 molecules cm-3 s-1 on two days. The most important sink for OH, and the largest source of peroxy radicals, was the oxidation of NMHCs, in particular, of isoprene and the monoterpenes.
Der Mangel von Faktor VIII (FVIII) führt zur häufigsten Gerinnungsstörung, der Hämophilie A. Die rekombinante Expression von FVIII für gentherapeutische Ansätze oder zur Herstellung von FVIII ist zwei bis drei Größenordnungen niedriger verglichen mit anderen Proteinen vergleichbarer Größe. Die Ursachen für die geringe Expression liegen zum großen Teil an der ineffizienten Transkription und dem ineffizientem intrazellulären Transport. (1) Im Rahmen der Untersuchung der FVIII-Sekretion, konnte durch Verwendung von FVIII-GFP Fusionsproteinen zum ersten Mal gezeigt werden, wie FVIII in lebenden Zellen transportiert wird. Außerdem wurde anhand von vergleichenden Immunfluoreszensfärbungen, FVIII-Messungen und Westernblotanalysen demonstriert, dass weder bei der B-Domäne deletierten noch bei der Volllängenvariante signifikante Unterschiede zwischen den GFP-fusionierten und Wildtyp-FVIII-Varianten messbar waren. Offensichtlich wird die Funktionalität von FVIII durch die C-terminal fusionierte GFP-Domäne nicht eingeschränkt. In ersten Lebendzellanalysen konnte gezeigt werden, dass sich FVIII in primären Zellen und Zelllinien hauptsächlich im ER befindet und eine für lumenale ER-Proteine charakteristischen Mobilität aufweist. Beim frühen sekretorischen Transport zeigte sich bei Temperaturblock-Experimenten eine verlängerte Dauer der Akkumulation in ER-Exit-Sites und eine vergleichsweise niedrige Frequenz von ER-Golgi-Bewegungen. Es konnte zum ersten Mal der Nachweis von FVIII-Transport durch vesikuläre tubuläre Cluster erbracht werden. Die Ergebnisse deuten darauf hin, dass der möglicherweise durch Faltungsprobleme blockierte Austritt aus dem ER das Hauptproblem des ineffizienten FVIII-Transports zu sein scheint und weniger der intrazelluläre Transport an sich. Mittels siRNA-Silencing wurde außerdem die überwiegende Beteiligung von COPI am intrazellulären Transport von FVIII deutlich, dessen Herunterregulierung zu einer 78 prozentigen Reduktion der FVIII-Sekretion im Gegensatz zu 32 Prozent bei COPII führte. Dagegen konnte durch Herunterregulierung der Expression der p24-Cargo-Rezeptor Familienmitglieder p24 und p26 und der Clathrin Adapterproteine µ- und -Adaptin bzw. durch physiologischen Knock-out im Falle von ER-Exit-Rezeptor MCFD2 kein Einfluß auf die FVIII-Sekretion festgestellt werden. (2) Als Alternative zu dem ineffizienten FVIII-Expressionsystem in unphysiologischen Zelllinien, bieten primäre Endothelzellen den Vorteil einer hocheffizienten FVIII-Sekretion. Zur Verwendung bei der rekombinanten Produktion benötigt man allerdings eine kontinuierlich wachsende gut charakterisierte Zelllinie. Zur Immortalisierung wurden aus Nabelschnurblut gewonnene Endothelprogenitorzellen mit der aktiven Untereinheit der humanen Telomerase (hTERT) transduziert. Trotz erfolgreicher Transduktion und langfristiger Expression von hTERT, welche im TRAP-Assay normale Aktivität zeigte, gingen die Zellen nach der natürlichen Teilungsspanne in die Seneszenz über. Möglicherweise wird noch ein weiteres Immortalisierungsgen benötigt oder hTERT ist durch die ektopischen Expression in diesen Endothelzellen nicht funktionell. (3) Der Einsatz hämatopoetischer Stammzellen für gentherapeutische Ansätze zur Expression von humanen FVIII ist bislang aufgrund niedriger Expressionseffizienz der Vektoren limitiert. Es wurden daher die Kombinationen verschiedener transkriptioneller und posttranskriptioneller Elemente in FVIII-Expressionsvektoren ausgetestet. Hierbei zeigte sich, dass die Verwendung einer 5’ untranslatierten Region (5’UTR) des hämatopoetisch exprimierten FXIIIA-Gens die FVIII-Sekretion in verschiedenen Zelllinien und primären Zellen deutlich steigerte. Am stärksten war die Wirkung in primären Monozyten, in denen die FVIII-Expression den 6fachen Wert im Vergleich zum Ursprungsvektor ohne 5’UTR erreichte. Leberzellen stellen weitere attraktive Zielzellen für gentherapeutische Ansätze dar, da Sie den primären physiologischen Ort der FVIII-Synthese darstellen. Die häufig für Gentherapievektoren verwendeten ubiquitär exprimierenden viralen Promotoren bewirken zwar hohe Expression in den transduzierten Zellen, haben allerdings den Nachteil durch ektopische Expression vermehrt Immunantworten auszulösen und durch starke Interaktion mit benachbarten Promotoren der Integrationsstelle im Genom möglicherweise tumorgene Effekte zu verursachen. Bei der Untersuchung verschiedener physiologischer Promotoren im Vergleich zum viralen CMV Promotor in Leberzellen konnte mit dem zum ersten mal getesteten minimalen FVIII-Promoter in einem lentiviralen Vektor der dritten Generation in Leberzelllinien eine vergleichsweise hohe Expression von 0,5 IU/ml FVIII /106 Zellen erzielt werden. Der FVIII-Promoter ist daher geeignet für eine lebergerichtete Expression und minimiert dabei das potentielle Risiko der häufig verwendeten ubiquitären viralen Promotoren.
Correction to: Infection (2020) 48:723–733 https://doi.org/10.1007/s15010-020-01469-6. The original version of this article unfortunately contained a mistake. In this article the authors Dirk Schürmann at affiliation Charité, University Medicine, Berlin, Olaf Degen at affiliation University Clinic Hamburg Eppendorf, Hamburg and Heinz-August Horst at affiliation University Hospital Schleswig–Holstein, Kiel, Germany were missing from the author list. The original article has been corrected.
Simple Summary: Renal insufficiency is frequently seen in newly diagnosed multiple myeloma and can be due to the disease itself but also caused by medical interventions or infections. Patients with severe renal insufficiency are known to have an adverse prognosis, but recently, it was shown that even moderately impaired kidney function can have long-term sequelae. Achieving quick disease control by effective antimyeloma therapy can lead to the recovery of renal function. We investigated the kidney-specific variables in a large cohort of 770 myeloma patients receiving three different three-drug regimens for initial myeloma treatment to learn more about the differential effects on kidney function in an early disease phase. All regimens had a positive impact on kidney function without a difference in the proportion of patients who reached normal renal function after three cycles. Interestingly, patients who received bortezomib, lenalidomide, and dexamethasone tended to have higher risk for a worse renal function following induction when compared to the initial values.
Abstract: Background: Preservation of kidney function in newly diagnosed (ND) multiple myeloma (MM) helps to prevent excess toxicity. Patients (pts) from two prospective trials were analyzed, provided postinduction (PInd) restaging was performed. Pts received three cycles with bortezomib (btz), cyclophosphamide, and dexamethasone (dex; VCD) or btz, lenalidomide (len), and dex (VRd) or len, adriamycin, and dex (RAD). The minimum required estimated glomerular filtration rate (eGFR) was >30 mL/min. We analyzed the percent change of the renal function using the International Myeloma Working Group (IMWG) criteria and Kidney Disease: Improving Global Outcomes (KDIGO)-defined categories. Results: Seven hundred and seventy-two patients were eligible. Three hundred and fifty-six received VCD, 214 VRd, and 202 RAD. VCD patients had the best baseline eGFR. The proportion of pts with eGFR <45 mL/min decreased from 7.3% at baseline to 1.9% PInd (p < 0.0001). Thirty-seven point one percent of VCD versus 49% of VRd patients had a decrease of GFR (p = 0.0872). IMWG-defined “renal complete response (CRrenal)” was achieved in 17/25 (68%) pts after VCD, 12/19 (63%) after RAD, and 14/27 (52%) after VRd (p = 0.4747). Conclusions: Analyzing a large and representative newly diagnosed myeloma (NDMM) group, we found no difference in CRrenal that occurred independently from the myeloma response across the three regimens. A trend towards deterioration of the renal function with VRd versus VCD may be explained by a better pretreatment “renal fitness” in the latter group.
Background: Computed tomography (CT) allows estimation of coronary artery calcium (CAC) progression. We evaluated several progression algorithms in our unselected, population-based cohort for risk prediction of coronary and cardiovascular events.
Methods: In 3281 participants (45–74 years of age), free from cardiovascular disease until the second visit, risk factors, and CTs at baseline (b) and after a mean of 5.1 years (5y) were measured. Hard coronary and cardiovascular events, and total cardiovascular events including revascularization, as well, were recorded during a follow-up time of 7.8±2.2 years after the second CT. The added predictive value of 10 CAC progression algorithms on top of risk factors including baseline CAC was evaluated by using survival analysis, C-statistics, net reclassification improvement, and integrated discrimination index. A subgroup analysis of risk in CAC categories was performed.
Results: We observed 85 (2.6%) hard coronary, 161 (4.9%) hard cardiovascular, and 241 (7.3%) total cardiovascular events. Absolute CAC progression was higher with versus without subsequent coronary events (median, 115 [Q1–Q3, 23–360] versus 8 [0–83], P<0.0001; similar for hard/total cardiovascular events). Some progression algorithms added to the predictive value of baseline CT and risk assessment in terms of C-statistic or integrated discrimination index, especially for total cardiovascular events. However, CAC progression did not improve models including CAC5y and 5-year risk factors. An excellent prognosis was found for 921 participants with double-zero CACb=CAC5y=0 (10-year coronary and hard/total cardiovascular risk: 1.4%, 2.0%, and 2.8%), which was for participants with incident CAC 1.8%, 3.8%, and 6.6%, respectively. When CACb progressed from 1 to 399 to CAC5y≥400, coronary and total cardiovascular risk were nearly 2-fold in comparison with subjects who remained below CAC5y=400. Participants with CACb≥400 had high rates of hard coronary and hard/total cardiovascular events (10-year risk: 12.0%, 13.5%, and 30.9%, respectively).
Conclusions: CAC progression is associated with coronary and cardiovascular event rates, but adds only weakly to risk prediction. What counts is the most recent CAC value and risk factor assessment. Therefore, a repeat scan >5 years after the first scan may be of additional value, except when a double-zero CT scan is present or when the subjects are already at high risk.
Fragment mass distributions for fission after full momentum transfer were measured in the reactions of 30Si,34,36 S,31P,40Ar + 238U at bombarding energies around the Coulomb barrier. Mass distributions change significantly as a function of incident beam energy. The asymmetric fission probability increases at sub-barrier energy. The phenomenon is interpreted as an enhanced quasifission probability owing to orientation effects on fusion and/or quasifission. The evaporation residue (ER) cross sections were measured in the reactions of 30Si + 238U and 34S + 238U to obtain information on fusion. In the latter reaction, significant suppression of fusion was implied. This suggests that fission events different from compound nucleus are included in the masssymmetric fragments. The results are supported by a model calculation based on a dynamical calculation using Langevin equation, in which the mass distribution for fusion-fission and quasifission fragments are separately determined.
Fission fragment mass distributions were measured in heavy-ion induced fissions using 238U target nucleus. The measured mass distributions changed drastically with incident energy. The results are explained by a change of the ratio between fusion and qasifission with nuclear orientation. A calculation based on a fluctuation dissipation model reproduced the mass distributions and their incident energy dependence. Fusion probability was determined in the analysis, and the values were consistent with those determined from the evaporation residue cross sections.